FITISH: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of FITISH’s website, https://fitish.com, FDA Establishment Identifier (FEI) 3044018836, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “FITISH” on the pictured label, suggesting FITISH is the compounder of those drugs when in fact it is not.”

2. 2

   ““Semaglutide is the active ingredient in ozempic” [sic]”

3. 3

   ““Tirzepatide is the active ingredient in Mounjaro® and Zepbound®””

4. 4

   “Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

fitish.com returned a live storefront when we checked in August 2026, selling compounded semaglutide and tirzepatide, oral tirzepatide tablets, GLP-1 microdosing, NAD+ and sermorelin alongside a beauty and merchandise range. We did not review every page on the site.

The [sic] is FDA's, and it tells you how these letters are built. Nobody rewrote the sentence, softened it or summarised it — an agency lawyer copied a lowercase line out of a product description and put it in a federal letter with a note that the error was the company's. That is worth knowing before you read any page in this collection, because it sets the scale. These are not investigations into how medicines were made. They are readings of website copy, sometimes a slogan, sometimes a fragment, occasionally a typo. A letter can therefore land on a company that is doing very little wrong in ordinary terms, and a company with no letter is not thereby endorsed — it may simply have written more careful sentences. Use the letter for what it reliably shows: on the date FDA looked, this page claimed an approval the compounded product did not have. Judge the price on its own.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence FITISH failed to respond.